Moleculin Completes Phase 2/3 AML Trial Enrollment, Eyes 2027 Data Readout
Event summary
- Moleculin Biotech completed enrollment in Part A of its Phase 2/3 MIRACLE trial for relapsed/refractory AML, with 89 subjects enrolled.
- The trial is on track for a comprehensive data readout in Q1 2027.
- Part A population expected to have a 50/50 split between 'fit' and 'unfit' subjects, shifting from an initial 70/30 split.
- Annamycin continues to show absence of cardiotoxicity in blinded data.
- MIRACLE trial compares Annamycin plus cytarabine to a control arm of cytarabine plus placebo.
The big picture
Moleculin's rapid enrollment in the MIRACLE trial underscores the unmet need in relapsed/refractory AML and the strong engagement from investigators. The shift in subject composition to more 'unfit' patients presents a more challenging environment for achieving treatment responses but may provide valuable insights into Annamycin's potential. The absence of cardiotoxicity continues to differentiate Annamycin from conventional anthracyclines, positioning it as a potential alternative in the AML treatment landscape.
What we're watching
- Efficacy Insights
- How the 50/50 split between 'fit' and 'unfit' subjects will impact efficacy insights for Annamycin.
- Regulatory Pathway
- Whether the single-cycle therapy approach in MIRACLE will meet FDA expectations for approval.
- Execution Risk
- The pace at which Moleculin can secure additional financing to advance the MIRACLE trial.
Related topics